European Union: Second Medical Use Claims For Devices – An Uneven Playing Field?

Last Updated: 7 November 2014
Article by Carpmaels & Ransford

European patent law offers extra protection for pharmaceuticals that is not available for medical devices. Second medical use claims for pharmaceuticals are routinely accepted in Europe, whereas the same style of claim is generally not permissible for medical devices. Recent case law has seen a shift towards rewarding new uses for existing medical devices, but achieving such protection requires care during prosecution.

Novel and inventive methods of treatment involving a medical device or a pharmaceutical cannot be patented in Europe due to a statutory exclusion, unlike in the US. Some compensation is provided through the granting of second medical use claims, which protect the product only when it is intended for use in an excluded method of treatment. However, there is an inconsistency between the way European law treats medical devices and pharmaceuticals. Obtaining second medical use claims for medical devices is challenging in Europe, whereas the same style of claim is generally permissible for pharmaceuticals.

This uneven playing field was set down when the EPC was drafted, and recent cases have confirmed that it is challenging to get protection for new and inventive methods of using a medical device. This inconsistency can cause significant commercial problems where the device itself is not patentable. Thankfully, there are some routes for gaining a degree of protection for new methods involving a known medical device at the EPO.

The origin of the inconsistency: Articles 53(c) and 54(4) and (5) EPC

The distinction between second medical use claims for pharmaceuticals and medical devices originates from the inconsistency between the broad exclusion in Article 53(c) EPC and the relatively narrow range of second medical use claims permitted by Article 54(4) & (5) EPC.

Article 53(c) EPC states that:

"European patents shall not be granted in respect of:

(c) methods for the treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body; this provision shall not apply to products, in particular substances or compositions, for use in any of these methods." (emphasis added)

As a consequence of the use of the expression "in particular", Article 53(c) EPC indicates that the term "products" is not limited to "substances" or "compositions" and so methods of using medical devices can also be excluded.

Protection can be obtained for medicinal products subject to the usual patentability requirements. Therefore a new pharmaceutical or a new medical device would not be excluded from patentability on the basis of this article. The problem comes where the pharmaceutical or medical device is not new and instead the invention lies in the way it is used.

Articles 54(4) and (5) EPC provide an exemption to the normal laws of novelty for a substance or composition intended for medical uses:

"(4) Paragraphs 2 and 3 shall not exclude the patentability of any substance or composition comprised in the state of the art, for use in a method referred to in Article 53(c), provided that its use for any such method is not comprised in the state of the art.

(5) Paragraphs 2 and 3 shall not exclude the patentability of any substance or composition referred to in paragraph 4 for any specific use in a method referred to in Article 53(c), provided that such use is not comprised in the state of the art." (emphasis added)

It is here that the inconsistency appears. Article 53(c) EPC explicitly excludes any therapeutic use of a product (which includes medical devices), whereas Articles 54(4) and (5) EPC only apply to "substances" and "compositions". The EPO's Boards of Appeal have held that this inconsistency means that the novelty generating provisions of Article 54(4) and (5) EPC cannot be used for new medical uses of known products which are not substances or compositions (e.g. medical devices). Therefore, where a device is known from the prior art, a second medical use claim directed towards that device for use in a novel and inventive method of treatment would be held to lack novelty over the known device. This is in stark contrast to the situation for a known pharmaceutical, where a second medical use claim would be allowable for the compound when intended for use in a novel and inventive method of treatment.

What is a substance or composition?

In order to decide whether an invention can be protected by using a second medical use claim, it is necessary to first decide whether the invention can be classified as a "substance" or "composition". Several cases from the Boards of Appeal show that the terms "substance" and "composition" are considered narrowly. In decision T1069/11 the second medical use claim was directed towards a "stent for use in prevention of restenoses of a wall (3) of a blood vessel having atheromatous plaque". The stent was a finished product that did not include any active ingredient and so it was found not to qualify as a substance or composition by the Board. Likewise, in T1099/09, a "strip made from biocompatible material" for use in the treatment of female urinary incontinence was also found to be neither a "substance" nor a "composition".

Further interpretation of the meaning of "substance" or "composition" was provided in decision T2003/08. The Board stated that Articles 54(4) and (5) EPC should apply to claims which qualify as "chemical entities" or compositions of chemical entities. These chemical entities should provide the means by which a therapeutic effect is achieved. Thus, the claimed "use of a specific ligand for human immunoglobulin in the manufacture of a column having said ligand coupled thereto for the treatment of a patient suffering from dilated cardiomyopathy," was interpreted as a second medical use claim. The specific ligand, the means by which the therapeutic effect was achieved, was a chemical entity and therefore was to be considered to be a "substance" or "composition". The Board found that the "column" (a medical device) merely served as a carrier for the ligand and was not instrumental in achieving the therapeutic effect, but nonetheless allowed the second medical use claim in relation to the ligand for use with the column.

The requirement in T2003/08 for the therapeutic effect to be achieved via a "chemical entity" goes beyond the position of the Enlarged Board of Appeal in G5/83, which simply held that the "substance or composition" itself must have a therapeutic effect. In any case, a claim directed towards a new use of a known substance or composition together with a device, where the substance itself provides the therapeutic effect, could be permissibly formatted as a second medical use claim.

G2/08 increased the possibilities for protecting new medical uses involving a device

The Enlarged Board of Appeal decision G2/08 held that where it is already known to use a medicament to treat an illness, Article 54(5) EPC allows this medicament to be patented for use in a different type of treatment of the same illness. This decision confirmed that second medical use claims can be novel solely due to the presence of a new dosage regimen or a new mode of administration.

G2/08 opened up a whole new range of options for gaining protection for a method of using a medical device. While the second medical use claim must refer to a "substance" or "composition" – i.e. a chemical entity – the method can specify that the chemical entity is used in conjunction with a device. For example, claims directed towards a drug for use a method of treatment in which the drug was administered via a device can now be protected using Articles 54(4) and (5) EPC. Such a claim can be both novel and inventive solely by virtue of the reference to its use with the device. Therefore, careful claim drafting can provide a degree of protection for a drug intended specifically for use in the particular device.

Carpmaels & Ransford LLP have had some success in this area. For example, in EP2227257 the second medical use claim read:

"A radionuclide brachytherapy source (RBS) for use in a method of irradiating a target of an eye in a patient, wherein said RBS is present in a cannula according to claim 1, the method comprising inserting said cannula into a potential space under a Tenon's capsule of the eye of the patient, the cannula having the RBS at a treatment position, whereby the RBS is positioned over the target, and the RBS irradiates the target".


Securing patent protection for a new therapeutic use of a known device is not straightforward at the EPO. Nonetheless, there are some options for obtaining protection for the new medical use of a known device where a substance or composition is used as a part of the therapeutic method.

Carpmaels & Ransford LLP is a leading firm of European patent attorneys based in London. For more information about our firm and our practice, please visit our website at

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.